| Followers | 33 |
| Posts | 3011 |
| Boards Moderated | 0 |
| Alias Born | 07/29/2015 |
Wednesday, October 21, 2020 4:31:51 PM
Why all this good news, but dropped back down to yearly low levels?
Are they diluting? Insider selling? Future offerings? Any insight?
$JAGX
Are they diluting? Insider selling? Future offerings? Any insight?
$JAGX
Honesty is the best policy
DD Support Board and Fraud Research Team
Recent JAGX News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 01:10:06 PM
- Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split • ACCESS Newswire • 04/27/2026 01:00:00 PM
- Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) • ACCESS Newswire • 04/24/2026 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/21/2026 12:22:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 11:35:12 AM
- Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders • ACCESS Newswire • 04/20/2026 08:15:00 PM
- Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs • ACCESS Newswire • 04/13/2026 12:30:00 PM
- Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates • ACCESS Newswire • 04/10/2026 12:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 09:04:50 PM
- Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs • ACCESS Newswire • 04/08/2026 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/07/2026 09:08:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 12:35:22 PM
- Jaguar Health Reports 2025 Financials • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/07/2026 10:10:28 AM
- Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress • ACCESS Newswire • 04/02/2026 01:00:00 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2026 08:19:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/24/2026 09:06:18 PM
- FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) • ACCESS Newswire • 03/18/2026 01:00:00 PM
- Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression • ACCESS Newswire • 03/16/2026 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/13/2026 08:59:50 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts • ACCESS Newswire • 03/11/2026 01:00:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 01:05:16 PM
- Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants • ACCESS Newswire • 03/09/2026 01:00:00 PM
